MedTrace Logo

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of ASB17061 Capsules in Adult Subjects With Atopic Dermatitis

NCT01756898 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 370

Last updated 2021-02-16

Study results available
· View outcomes & findings →

Summary

The purpose of this research study is to gather scientific information about the effectiveness of the study drug, ASB17061 capsules, when compared to placebo in adult subjects with atopic dermatitis.

Conditions

Interventions

DRUG

5 mg ASB17061

Oral administration of 5 mg ASB17061 taken once daily for 28 consecutive days.

DRUG

Placebo

Oral administration of placebo taken once daily for 28 consecutive days.

DRUG

10 mg ASB17061

Oral administration of 10 mg ASB17061 taken once daily for 28 consecutive days.

DRUG

20 mg ASB17061

Oral administration of 20 mg ASB17061 taken once daily for 28 consecutive days.

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Leader · Daiichi Sankyo

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-28
Primary Completion
2014-01-14
Completion
2014-01-14

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01756898 on ClinicalTrials.gov